GET DAILY SIGNALSAmerican Healthcare REIT (AHR) Tops Estimates and Raises Full-Year Guidance
Key Takeaways
- American Healthcare REIT reported normalized funds from operations (NFFO, a key profitability measure for real estate investment trusts) of $0.58 per diluted share, topping the consensus estimate of $0.56 and rising roughly 32% from $0.44 a year earlier.
- Total revenues reached $742.15 million, up 29.5% year over year, though they came in below the consensus forecast of approximately $770.48 million.
- Total portfolio same-store net operating income (NOI, a measure of property-level profitability) grew 13.8%, led by 28.2% growth in the senior housing operating portfolio (SHOP) and 15.7% in integrated senior health campuses (ISHC).
- Management raised full-year 2026 guidance, including NFFO per diluted share to a range of $2.23 to $2.26, up from $2.15 to $2.19 previously.
- The company reduced its net debt-to-annualized adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio to 1.9x from 2.5x in the prior quarter, reflecting a stronger balance sheet.
- For more detail on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Looking for additional market ideas? Explore Trending AI Robots to discover AI-driven trading strategies.
Earnings Context and Why It Matters
American Healthcare REIT's third quarter 2026 results, released on November 5, 2026, mark another step in the company's expansion within the senior housing sector. The report matters because it tests whether the company can sustain double-digit same-store NOI growth while absorbing a large pipeline of acquisitions. Over the prior year, AHR has consistently outpaced consensus NFFO expectations, and this quarter's guidance increase signals confidence in continued momentum. Investors are also watching how the company funds its growth, given sizable equity issuance and a recent leadership transition that included a new chief financial officer and executive appointments across the management team. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, American Healthcare REIT posted normalized funds from operations of $0.58 per diluted share, exceeding the consensus estimate of $0.56. Total revenues came in at $742.15 million, a 29.5% increase from $572.94 million in the prior-year period, though slightly below the roughly $770 million analysts had expected. GAAP net income attributable to controlling interest was $31.2 million.
Property-level performance was a highlight. Total portfolio same-store NOI rose 13.8%, with the senior housing operating portfolio up 28.2% and integrated senior health campuses up 15.7%. The company completed roughly $1.69 billion in acquisitions of 17 senior housing operating properties during the quarter, bringing completed 2026 investments to approximately $2.07 billion.
Management raised full-year 2026 guidance across key metrics, lifting NFFO per diluted share to $2.23 to $2.26, NAREIT FFO (funds from operations as defined by the National Association of Real Estate Investment Trusts) to $2.13 to $2.16, and total portfolio same-store NOI growth to a range of 12.0% to 14.0%. The company also declared a quarterly cash distribution of $0.25 per share.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around AHR had been broadly favorable, supported by a string of quarters in which normalized FFO beat consensus estimates and by consistent same-store NOI growth. The company has outperformed the broader market year to date, reflecting investor confidence in its senior housing platform and acquisition strategy.
Post-earnings, the focus has centered on the tension between a clean NFFO beat and a revenue figure that fell short of consensus. While the stronger-than-expected profitability and raised guidance are positive signals, the top-line miss and the dilutive effects of significant equity issuance have tempered some of the enthusiasm. Management's commentary on the earnings call, including execution on the acquisition pipeline and balance sheet leverage, will likely continue to shape near-term investor interpretation.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch how American Healthcare REIT executes on its raised guidance and continues to convert its acquisition pipeline into same-store NOI growth. The company has indicated a pipeline of more than $1 billion in additional investments, but it has cautioned that the timing and completion of these transactions are not guaranteed and are excluded from current guidance.
Capital deployment and funding remain central themes. AHR has leaned on equity offerings and forward sale agreements through its at-the-market (ATM) program, which has strengthened liquidity but also increased share count and diluted per-share metrics. Monitoring whether the company continues to fund growth this way, and how efficiently it does so, will be important for assessing per-share earnings power.
On the operational side, pricing power and cost control across the senior housing portfolio will be key drivers. Sustained momentum in the SHOP and ISHC segments has been the engine of recent growth, and any shift in occupancy trends, labor costs, or operator performance could influence results. Finally, the leadership transition—including the new CFO and broader executive appointments—warrants attention as investors evaluate continuity in strategy and execution into 2027.
Using Tickeron’s AI Tools in My Analysis
In my research process, I often turn to Tickeron’s AI Screener to quickly filter through opportunities and benchmark names like AHR against peers. It’s a helpful way to incorporate technical patterns and fundamentals into the analysis without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AHR in upward trend: price rose above 50-day moving average on October 30, 2026
AHR moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend. In 13 of 16 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on AHR as a result. In 38 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for AHR just turned positive on October 12, 2026. Looking at past instances where AHR's MACD turned positive, the stock continued to rise in 17 of 24 cases over the following month. The odds of a continued upward trend are 71%.
The 10-day moving average for AHR crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +4.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where AHR advanced for three days, in 154 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 139 of 221 cases where AHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
AHR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.417) is normal, around the industry mean (3.134). P/E Ratio (83.928) is within average values for comparable stocks, (30.791). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). Dividend Yield (0.023) settles around the average of (0.050) among similar stocks. P/S Ratio (3.877) is also within normal values, averaging (6.013).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PublishingBooksMagazines
Advertisement